Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754905 | 0.76 | LMNA (0.31) | ALDH1A1CA12CA9CDC7 | |
| SCHEMBL5002981 | 0.71 | ALDH1A1 (0.37) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL3500581 | 0.71 | ALDH1A1 (0.37) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL1388602 | 0.69 | — | — | |
| SCHEMBL12210337 | 0.68 | TDP1 (0.45) | ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL4304574 | 0.68 | — | — | |
| SCHEMBL29919879 | 0.67 | CA12 (0.50) | KMT2AKDM4EMEN1CA12CA9 | |
| SCHEMBL2704680 | 0.67 | CA12 (0.50) | KMT2AKDM4EMEN1CA12CA9 | |
| SCHEMBL12702631 | 0.67 | MAPK13 (0.38) | ALDH1A1 | |
| SCHEMBL12702805 | 0.67 | MAPK13 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186349-B2 | Diaza heterocyclic compounds for phototherapy | MALLINCKRODT LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20120058954-A1 | Diaza Heterocyclic Compounds for Phototherapy | OCERA THERAPEUTICS LLC | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058954-A1 | Diaza Heterocyclic Compounds for Phototherapy | BAD, BID, CASP3 | HPGD 459/4885ALDH1A1 544/4885KMT2A 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.